While mutations in genes encoding RHO GTPases are rare in cancer, alternative mechanisms lead to the spurious activation of RHO pathways, which could add multiple regulatory layers controlling the steady-state levels and activation dynamics of RHO signaling elements. This evidence concerns the gene RHO and cancer.